Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Jinshuangqi probiotics to reduce GI adverse reactions during Helicobacter pylori eradication
ChiCTR2500108063Phase 4Not yet recruiting
- Sponsor
- Southern Medical University Shenzhen Hospital
- Start
- Aug 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of jinshuangqi in Helicobacter pylori infection (2 arms), sponsored by Southern Medical University Shenzhen Hospital. Primary endpoint: Incidence rate of digestive tract adverse reactions related to Hp eradication therapy. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
jinshuangqi
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2500108063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108063.